ABPI Patient Organisation Forum
Sharon Kell rang in to this interesting virtual meeting of [...]
ABPI Patient Organisation Forum: NICE methods and processes review
KCSN is a member of the Association of the British Pharmaceutical [...]
Safety and efficacy of tivozanib–nivolumab combination in patients with metastatic kidney cancer
In this phase 1b/2 study the researchers looked at a [...]
Cancer52 All Members Meeting – NHS Long Term Plan and NICE Methods and Processes
The Cancer52 All Members Meeting took place on Wednesday 16th [...]
National Voices Workshop
Steve Pointon attended a workshop last week organised by National [...]
Immune-related adverse events from cabozantinib plus atezolizumab as first-line treatment for advanced kidney cancer
The COSMIC-021 clinical trial investigated a combination of cabozantinib and [...]
Cabozantinib plus atezolizumab for non-clear cell renal cell carcinoma
In this video interview with Dr Monty Pal from the [...]
Treatment selection for metastatic kidney cancer based on gene expression
The discovery of a reliable biomarker for metastatic renal cell [...]
Avelumab plus axitinib combintion approved for untreated advanced kidney cancer in Scotland
The Sottish Medicine Consortium (SMC) have issued a final decision to recommend [...]
Selection of advanced kidney cancer patients for nephrectomhy
In this study, 6,043 patients with metastatic renal cell carcinoma [...]
